1. Home
  2. LIQT vs TVRD Comparison

LIQT vs TVRD Comparison

Compare LIQT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiqTech International Inc.

LIQT

LiqTech International Inc.

HOLD

Current Price

$0.57

Market Cap

28.8M

Sector

Technology

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$1.87

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIQT
TVRD
Founded
2004
2017
Country
Denmark
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
27.5M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
LIQT
TVRD
Price
$0.57
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$4.30
$29.50
AVG Volume (30 Days)
121.3K
339.1K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.01
EPS
N/A
N/A
Revenue
N/A
$911,000.00
Revenue This Year
$42.12
N/A
Revenue Next Year
$63.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
959.30
52 Week Low
$0.52
$1.50
52 Week High
$3.35
$43.65

Technical Indicators

Market Signals
Indicator
LIQT
TVRD
Relative Strength Index (RSI) 39.35 40.71
Support Level N/A $1.70
Resistance Level $0.74 $2.04
Average True Range (ATR) 0.06 0.13
MACD 0.00 0.03
Stochastic Oscillator 19.57 52.97

Price Performance

Historical Comparison
LIQT
TVRD

About LIQT LiqTech International Inc.

LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: